# How to Spot Inflated or Unverifiable Claims in a Healthcare Pitch > Healthcare pitches frequently contain overstated clinical data, misrepresented regulatory status, and cherry-picked market numbers that can destroy investor capital. This guide gives you a systematic, source-by-source framework to verify every major claim before you write a check. # How to Spot Inflated or Unverifiable Claims in a Healthcare Pitch The single most reliable way to spot inflated or unverifiable claims in a healthcare pitch is to cross-reference every major assertion against its named primary source before you accept it as fact. Most misrepresentations collapse the moment you open FDA databases, ClinicalTrials.gov, SEC EDGAR, USPTO, or PubMed and compare what the founder said against what the record actually shows. The sections below walk you through each category of claim, exactly where to check, and the red flags that signal deliberate inflation. ## Why Are Healthcare Pitches Especially Prone to Inflated Claims? Healthcare combines technical complexity with high emotional stakes, which creates ideal conditions for exaggeration. Investors rarely have time to read a full clinical study, and founders know it. Regulatory timelines are long and opaque, market-size figures vary wildly depending on methodology, and intellectual property is genuinely hard to assess without patent expertise. These friction points are precisely where inflated claims hide. ## How Do You Verify Clinical and Scientific Claims? Start with ClinicalTrials.gov (clinicaltrials.gov), the U.S. National Library of Medicine registry where any trial involving a drug, device, or biological product that is conducted in the U.S. or seeking FDA approval must be registered. Search the company name or the intervention name and compare the registered primary endpoints against what the pitch deck claims as outcomes. Common manipulations include: - Reporting a secondary endpoint as if it were the primary one - Citing Phase I safety data as efficacy evidence - Quoting p-values without sample size context - Referencing a completed trial that was actually terminated early for safety or futility After ClinicalTrials.gov, pull the underlying publication on PubMed (pubmed.ncbi.nlm.nih.gov). Check the journal impact factor and whether the study was peer-reviewed or only a preprint. Preprints carry no editorial validation and should never be presented as equivalent to published evidence. ## How Do You Check Regulatory Status Claims? FDA clearance, approval, and Breakthrough Designation are legally distinct and are frequently conflated in pitches. Use these specific databases: - **510(k) clearances and PMA approvals**: FDA's 510(k) database and PMA database at accessdata.fda.gov - **Breakthrough Therapy, Fast Track, or Orphan Drug designations**: FDA's search tools at fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review - **Drug approvals**: Drugs@FDA at accessdata.fda.gov/scripts/cder/daf A founder who says their device is "FDA approved" when it only has 510(k) clearance is either uninformed or misleading you. These are not interchangeable. A Breakthrough Designation means the FDA agreed to work closely with the company; it does not mean the product is approved or that approval is likely. ## How Do You Validate Intellectual Property Claims? Patent claims are among the most inflated in early-stage healthcare pitches. "Broad patent protection" and "strong IP moat" are phrases that require verification. Use the USPTO Patent Full-Text Database (patents.google.com or ppubs.uspto.gov) to find every patent and application the company has filed. Look for: - Whether claims are granted or only pending (pending claims have zero legal protection yet) - The breadth of the independent claims, not just the abstract - Expiration dates relative to the product's expected commercial window - Whether any claims have been challenged in inter partes review proceedings (searchable at ptab.darts-ip.com or the USPTO PTAB portal) ## How Do You Evaluate Market Size Numbers? Bottom-up market sizing built from patient prevalence, diagnosis rates, and realistic pricing is far more credible than top-down figures sourced from a single market research firm. Ask the founder to walk you through their TAM calculation step by step. Red flags include citing a single proprietary report without naming the methodology, using global figures when the product only has U.S. clearance, and conflating the total disease burden with the addressable market for one specific product. ## How Do You Assess Financial and Partnership Claims in SEC Filings? For any company that has raised from institutional investors or is publicly traded, pull filings from SEC EDGAR (efts.sec.gov). Revenue figures, partnership agreements, and milestone payments should be disclosed in 10-K or 10-Q filings. If a founder claims a signed partnership with a major health system or payer, ask to see the agreement or at least the press release. Vague claims about "letters of intent" or "pilot agreements" that appear nowhere in public records are a consistent warning sign. ## What Are the Five Most Common Inflated Claims to Watch For? 1. Calling a feasibility or pilot study a "clinical trial" without specifying phase or control conditions 2. Citing a market size that includes conditions your product does not treat 3. Presenting a pending patent application as granted protection 4. Describing regulatory consultation meetings as regulatory approvals 5. Quoting a five-year-old partnership that has produced no disclosed revenue ## Due Diligence Checklist: Verifying a Healthcare Pitch - [ ] Search ClinicalTrials.gov for every named trial; confirm primary endpoints match pitch claims - [ ] Pull the peer-reviewed publication on PubMed; confirm it is not a retracted or preprint-only source - [ ] Confirm FDA status in the correct database (510(k), PMA, or Drugs@FDA) using the exact device or drug name - [ ] Search USPTO for every claimed patent; note granted versus pending and expiration dates - [ ] Request a bottom-up TAM breakdown with sourced prevalence and pricing data - [ ] Check SEC EDGAR for any filed disclosures that contradict or do not mention claimed milestones - [ ] Ask for unredacted copies of any partnership or licensing agreements cited as traction ## How Can You Automate This Verification Process? Running this checklist manually across six or more primary sources for every deal takes three to five hours per pitch at minimum. MedFuel Intel uses AI-driven due diligence reports to cross-reference FDA databases, ClinicalTrials.gov, USPTO, SEC EDGAR, and PubMed simultaneously, surfacing discrepancies between pitch claims and primary-source records in minutes rather than days. Run a free Red Flag Screener on your next healthcare deal at [medfuelintel.com](https://medfuelintel.com) and see exactly which claims hold up and which do not before your next meeting. --- *Informational only, not investment advice.* --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/how-to-spot-inflated-or-unverifiable-claims-in-a-healthcare-pitch). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.